225 related articles for article (PubMed ID: 9159329)
1. Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma.
Chou CY; Huang SC; Tsai YC; Hsu KF; Huang KE
Gynecol Oncol; 1997 May; 65(2):225-31. PubMed ID: 9159329
[TBL] [Abstract][Full Text] [Related]
2. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
4. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
5. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
6. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells.
Wang J; Ohara N; Takekida S; Xu Q; Maruo T
Hum Reprod; 2005 Jun; 20(6):1456-65. PubMed ID: 15760954
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis.
Huang SC; Yu CH; Huang RT; Hsu KF; Tsai YC; Chou CY
Obstet Gynecol; 1996 Jun; 87(6):1019-24. PubMed ID: 8649683
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
Leiser AL; Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi DS; Soslow RA
Gynecol Oncol; 2006 Apr; 101(1):86-91. PubMed ID: 16289259
[TBL] [Abstract][Full Text] [Related]
11. Cell proliferation and apoptosis in human uterine leiomyomas and myometria.
Dixon D; Flake GP; Moore AB; He H; Haseman JK; Risinger JI; Lancaster JM; Berchuck A; Barrett JC; Robboy SJ
Virchows Arch; 2002 Jul; 441(1):53-62. PubMed ID: 12111201
[TBL] [Abstract][Full Text] [Related]
12. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells.
Zhu XQ; Lv JQ; Lin Y; Xiang M; Gao BH; Shi YF
Gynecol Oncol; 2007 Jun; 105(3):650-6. PubMed ID: 17368523
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas.
Poncelet C; Fauvet R; Feldmann G; Walker F; Madelenat P; Darai E
J Surg Oncol; 2004 May; 86(2):84-90. PubMed ID: 15112250
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up.
Mills AM; Ly A; Balzer BL; Hendrickson MR; Kempson RL; McKenney JK; Longacre TA
Am J Surg Pathol; 2013 May; 37(5):634-42. PubMed ID: 23552380
[TBL] [Abstract][Full Text] [Related]
15. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review.
Yanai H; Wani Y; Notohara K; Takada S; Yoshino T
Pathol Int; 2010 Jul; 60(7):506-9. PubMed ID: 20594271
[TBL] [Abstract][Full Text] [Related]
16. [Study of the mechanism of mast cell increase in cellular leiomyoma of uterus].
Lü JQ; Zhu XQ; Dong K; Xiang M; Lin Y; Hu Y
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):390-3. PubMed ID: 17697600
[TBL] [Abstract][Full Text] [Related]
17. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density.
Hague S; Zhang L; Oehler MK; Manek S; MacKenzie IZ; Bicknell R; Rees MC
Clin Cancer Res; 2000 Jul; 6(7):2808-14. PubMed ID: 10914728
[TBL] [Abstract][Full Text] [Related]
18. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
19. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Lombardi G; Cimini V; Zullo F
Fertil Steril; 2005 Jul; 84(1):154-61. PubMed ID: 16009171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
